PROCYRION - Key Persons
Av Edidin, Ph.D. Senior Vice President, Development and Manufacturing Av brings over 25 years of experience in the research, development, and manufacture of medical devices and has introduced commercial products in the long-bone orthopaedic, spinal fixation and ablation, and catheter instrumentation areas. He is named on over 15 U.S. and foreign patents. Av received his Ph.D. in Biomedical Engineering from Cornell University. Read full bio
Job Titles:
- Member of the Board of Directors
- Founder and Managing Partner of View Ventures
Carter Meyer is the founder and Managing Partner of View Ventures, a venture capital fund investing in medical and health technologies. For the 14 years years prior to that, Mr. Meyer was the Chief Executive Officer of SHD Management, LLC ("SHD") which is the manager of three life science investment funds (Scientific Health Development, Ltd.; Scientific Health Development II, Ltd. and Scientific Health Development III, Ltd.) In addition to the board of directors of Procyrion, Mr. Meyer serves on the board of directors of Eirion and International Life Sciences LLC (d/b/a Artelon). Prior to SHD, Mr. Meyer was an attorney in private practice for over 12 years, most recently with Vinson & Elkins L.L.P., focusing on commercial transactions with substantial experience buying, selling, financing and making investments in both public and private entities. Mr. Meyer has a B.B.A. in finance from Texas Christian University and a J.D. from St. Mary's University School of Law.
Job Titles:
- Vice President, Product Development
Accomplished bioengineer and medical device entrepreneur with extensive experience in structural heart research; experience in world-class labs in both the US and Europe, developing enabling technologies for the treatment of valve disease; BS with highest honors from the Georgia Institute of Technology; PhD in Bioengineering from Rice University.
Job Titles:
- Senior Vice President, Clinical and Regulatory Affairs
Beth brings to Procyrion more than 20 years of experience as a global regulatory affairs leader, having played a key role in the approval of neuromodulation and cardiac devices. She has been integral in successful US and international registrations for clinical trials and commercial product approvals. Prior to Procyrion, Beth was Division Vice President, Regulatory Affairs for Abbott's Cardiac Arrhythmias and Heart Failure Business Unit. Prior to the acquisition of St. Jude Medical by Abbott, Beth held several roles in regulatory affairs culminating in her role as the Vice President of Global Regulatory Affairs for St. Jude Medical. She received a BS in Biomedical Engineering and a BA in Spanish from Texas A&M University.
Job Titles:
- CEO
- Member of the Board of Directors
- President
With over 30 years of experience in the medical device industry, Dr. Fain was the former Senior Vice President and Group President, Cardiovascular and Neuromodulation at Abbott following their acquisition of St. Jude Medical in 2017. Dr. Fain became Group President of St. Jude Medical in 2014. Dr. Fain received his M.D. from Stanford University School of Medicine.
With over 30 years of experience in the medical device industry, Dr. Fain was the former Senior Vice President and Group President, Cardiovascular and Neuromodulation at Abbott following their acquisition of St. Jude Medical in 2017. Dr. Fain became Group President of St. Jude Medical in 2014 where his responsibilities included the global sales, marketing, R&D, clinical and regulatory functions across the entire St. Jude Medical portfolio worldwide. Dr. Fain joined St. Jude Medical in 1997 as Vice President, Systems Development as part of the company's acquisition of Ventritex, Inc., a startup implantable defibrillator company where he had worked since 1987. After holding senior executive positions in Clinical, Regulatory and R&D for the Cardiac Rhythm Management Division (CRMD), he became President, CRMD in 2007 and was named President of the company's Implantable Electronic Systems Division in 2012 when its CRM/heart failure and neuromodulation divisions merged. Dr. Fain received his M.D. from Stanford University School of Medicine and holds a Sc.B. degree in applied math/biology from Brown University.
Job Titles:
- Member of the Board of Directors
Mr. Burbach, an accomplished medical device executive, joined Procyrion's Board as an Independent Director and Chairman in February 2016. From January 2006 to September 2014, Mr. Burbach served as president, chief executive officer, and director of Thoratec Corporation (NASDAQ: THOR), a company that develops, manufactures, and markets proprietary medical devices used for circulatory support. In addition, from 2004 to February 2013, Mr. Burbach served as a member of the board of directors of Digirad Corporation (NASDAQ: DRAD), a company focused on diagnostic imaging products. From April 2005 to January 2006, Mr. Burbach served as president and chief executive officer of Digirad Corporation. From July 2003 to April 2005, he served as president and chief executive officer of Bacchus Vascular, Inc., a developer of catheter-based medical devices. From January 2001 to July 2003, he served as chief executive officer of Philips Nuclear Medicine, a division of Philips Electronics, and, before its acquisition by Philips, worked for four years for ADAC Laboratories, most recently as president. Mr. Burbach also spent six years with the management consulting firm of McKinsey & Company, Inc., where he was a senior engagement manager in the firm's healthcare practice.
Sean Pinney, MD is the Philip J. and Harriet L. Goodhart Professor of Medicine and the Chief, Division of Cardiology at Mount Sinai Morningside. Prior to joining Mount Sinai Morningside, he held leadership positions at the University of Chicago Medical Center, where he served as Director of Heart Failure and Cardiac Transplantation, Director of the Richard P. Parrillo Family Center for Clinical and Translational Cardiology Research, and Co-Director of the Heart and Vascular Center. Prior to his time in Chicago, Pinney previously worked at Mount Sinai, where he served in many leadership roles from 2004 to 2020, including Director of Heart Failure and Transplantation for the Mount Sinai Health System, Fellowship Director of Advanced Heart Failure and Transplantation for The Mount Sinai Hospital, and Professor of Medicine for the Icahn School of Medicine at Mount Sinai.
Job Titles:
- Member of the Scientific Advisory Board
- Professor of Medicine at the George Washington University
Janani Rangaswami is a professor of medicine at the George Washington University (GWU) School of Medicine. She is the Chief of Nephrology at the Washington DC VA Medical Center. She completed her residency and chief residency in Internal Medicine at Einstein Medical Center, Philadelphia and a fellowship in Nephrology at Weill Cornell Medical Center, NY. She is the Chair for the Kidney Council of the American Heart Association, and led the AHA Scientific Statements on Cardio-Renal Syndrome (2019) and the Cardiorenal Benefits with the Newer Antidiabetic Agents in Kidney Disease (2020). She has authored several publications in cardiorenal medicine, and is the lead editor of two textbooks in this field: Textbook of Cardio-nephrology and the Textbook of Kidney Disease in the Cardiac Catheterization Laboratory. She has won several awards for teaching and leadership in her career, and also helped establish the Philadelphia Agreement on Gender Equality in Internal Medicine, which is a regional consortium to ensure gender equity in Internal Medicine training. She is a regular speaker at societal meetings in cardiology, endocrinology, and nephrology, and has presented her work in many national and international avenues.
Experienced venture-backed founder of three start-ups; McKinsey & Co. consultant with CV OR and cath-lab focused engagements; Ph.D. from Oxford University in Sensors, Sensor Fusion, Control Systems, and Artificial Vision.
Job Titles:
- Member of the Board of Directors
- Life Science Investor for Nearly Twenty Years at Sutter Hill Ventures
Jeff Bird has been a life science investor for nearly twenty years at Sutter Hill Ventures. In 2019, he formed Bluebird Ventures. Jeff received an MD and PhD (Cancer Biology) degree from Stanford Medical School, and was a Stanford undergraduate.
Jeff Bird has been a life science investor for nearly twenty years at Sutter Hill Ventures. In 2019, he formed Bluebird Ventures. He is on the board of two public companies, Portola Pharmaceuticals and Forty Seven, Inc. He served as CEO of Verinata, a developer of non-invasive prenatal diagnostics which was sold to Illumina. Prior to Sutter Hill Ventures, he was an executive at Gilead Sciences for 15 years, most recently as Senior Vice President of Business Operations which included global sales and marketing. Jeff received an MD and PhD (Cancer Biology) degree from Stanford Medical School, and was a Stanford undergraduate.
Job Titles:
- Member of the Scientific Advisory Board
- FACC Is the Section Head of Heart Failure, Transplant and Mechanical Circulatory Support at Henry Ford Hospital
Jennifer Cowger, MD, MS, FACC is the Section Head of Heart Failure, Transplant and Mechanical Circulatory Support at Henry Ford Hospital. She is also an Associate Professor at Wayne State University in Detroit, Michigan. She attended medical school at Ohio State University, then completed her residency at Duke University and cardiology fellowship at the University of Michigan. She also holds a masters in statistics from the University of Michigan. Dr. Cowger focuses on caring for patients with cardiomyopathy as well as those who have had - or are being considered for - a heart transplant or a heart left ventricular assist device (LVAD). She also specializes in cardiac sarcoidosis and cardiac amyloidosis. To ensure her patients have access to the latest therapies, she participates in clinical research and is an active member of prominent cardiac societies such as the American College of Cardiology, the Heart Failure Society of American, and the International Society for Heart and Lung Transplant.
Job Titles:
- Vice President, Quality Assurance
Katherine is an experienced Quality Assurance professional, highly knowledgeable and skilled in Quality Engineering and in developing, implementing and maintaining Quality Management Systems compliant with 21 CFR 820, ISO 13485 and international regulations for successful 510k / CE Mark device registration and PMA approval. Prior to Procyrion, Katherine was QA Director for IDEV Technologies (Division of Abbott Vascular) where she oversaw the quality program for IDEV's peripheral vascular stent products. Prior to IDEV, Katherine was Sr. QA Manager at Sulzer Intermedics (Subsidiary of Guidant Corporation). She received her MS in Engineering Management from University of South Florida and a BS in Mechanical Engineering from Louisiana State University.
Job Titles:
- Member of the Board of Directors
- Chairman and Founder of Fannin Innovation Studio
- President and CEO of the Aquinas Companies
Leo Linbeck III is the Chairman and Founder of Fannin Innovation Studio. Leo is also President and CEO of the Aquinas Companies, LLC, which sponsored Fannin for five years to validate its model before bringing in outside investors for scale-up. Leo graduated from the University of Notre Dame with both Civil Engineering and Liberal Arts degrees and received a Master's in Structural Engineering from the University of Texas. He earned his MBA from the Stanford University Graduate School of Business, graduating as the only student in its history to be both Valedictorian and winner of the Arbuckle Award (the person voted by his classmates to have made the greatest contribution to the school). Additionally, Leo teaches MBAs at Stanford's Graduate School of Business where he serves as a Lecturer and is a former adjunct professor at Rice University's Jones Graduate School of Business. Leo is also on the boards of several educational, community and nonprofit organizations.
Job Titles:
- Member of the Scientific Advisory Board
Manesh Patel, MD, Chief of the Division of Cardiology for Duke's Department of Medicine, is an associate professor of medicine, a member of the Duke Clinical Research Institute, and director of Interventional Cardiology and Cardiac Catheterization Labs across the Duke University Health System. His clinical interests include diagnostic and interventional coronary angiography, peripheral angiography, and endovascular intervention. He is involved in several clinical trials involving patients with cardiovascular disease and in cardiac imaging. Manesh is the chair of the American College of Cardiology Task Force for Appropriate Use Criteria for Cardiovascular Procedures, and is chair of the American Heart Association Diagnostic and Interventional Cath Committee. His interest in cardiac imaging, quality of care, and cardiac devices is evident in his research. His integration of these efforts into his roles at Duke was recognized in 2010 when he received the prestigious Duke Cardiology Fellowship Mentor Award. In 2011, he was named the endowed John Bush Simpson Assistant Professor of Cardiology, and in 2013, he received the Robert M. Califf Faculty Clinical Research Award. Manesh received his M.D. from Emory University, then attended Duke for residency, served as chief resident in medicine, and completed a fellowship in cardiology. He joined the faculty in 2006.
Job Titles:
- Member of the Board of Directors
- Partner at Gravitas Healthcare
Marc Chaput is a Partner at Gravitas Healthcare, a strategic advisory firm focused on emerging growth medical device companies. Prior to Gravitas, he was a Director in Cowen & Co.'s health care investment banking group, and prior to that he worked in the health care group at Deutsche Bank. He is also on the Advisory Committee of Sweetwater Capital Partners and represents the State of Texas on the Procyrion board. He holds a B.A. from Bates College and an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University.
Job Titles:
- Member of the Scientific Advisory Board
Nir Uriel, MD, MSc, an internationally recognized leader in heart failure, mechanical circulatory support, and heart transplantation, is Director of Advanced Heart Failure and Cardiac Transplantation at New York-Presbyterian.
Nir Uriel, MD, MSc, an internationally recognized leader in heart failure, mechanical circulatory support, and heart transplantation, is the Director of Advanced Heart Failure and Cardiac Transplantation at NewYork-Presbyterian. Dr. Uriel oversees heart failure programs at NewYork-Presbyterian's campuses in Manhattan, Queens, Brooklyn, and Westchester, with a goal to increase accessibility of care for those with advanced heart failure throughout the New York area. Dr. Uriel was born and raised in Israel, where he attended medical school. After serving for four years as a physician in the Israeli Defense Forces, he then completed his cardiology residency and fellowship. In 2008, he moved to New York to pursue fellowships at NewYork- Presbyterian/Columbia in cardiology, heart failure, transplant, and mechanical circulatory support and remained there as a faculty member until 2014. He then served as the Louis Block Professor of Medicine and Director of Heart Failure, Transplant and Mechanical Circulatory Support at the University of Chicago Medicine, where, in 2018, he and his Chicago team made history performing two triple organ transplants within 27 hours.
Job Titles:
- Member of the Scientific Advisory Board
Palak Shah, MD, MS is Medical Director of the Mechanical Circulatory Support (MCS) and Heart Failure Research programs at the Inova Heart and Vascular Institute and is an Associate Professor of Medicine at George Washington University (adj). His training encompassed multiple institutions: Georgetown University, George Washington University, and the University of Michigan. During cardiovascular medicine fellowship, he was elected to the Alpha Omega Alpha Honor's society and to solidify his research training, obtained a Masters in Clinical and Translational Research. His research is focused on the use of clinical risk prediction models, machine learning and biomarkers to improve outcomes of patients with advanced heart failure. In his translational lab, Dr. Shah's team performs protein and genomic based assays to develop circulating biomarkers with excellent translational capability. This led to him being co-awarded the 2021 James T. Willerson Award for top clinical science paper in Circulation. He has also served as a principal investigator or on the steering committee for multiple multicenter clinical trials. He was former Chair for the MCS Steering Committee of the International Society for Heart and Lung Transplantation (ISHLT). By better understanding and characterizing patients with advanced heart failure, mechanical circulatory support, or cardiac transplantation, his goals are to identify novel clinical management strategies as well as inform the development of newer therapeutics that improve long-term outcomes for patients living with heart failure.
Job Titles:
- Member of the Scientific Advisory Board
- Executive Manager of Cardiology at GenesisCare
Prof. Stephen Worthley is Executive Manager of Cardiology at GenesisCare in mainland Australia, leading a network of over 80 cardiologists and 6 practices. This role enables him (with his passion and exceptional leadership capabilities) to help shape and direct the future of healthcare. He practices procedural work in structural heart disease one day per week at the Royal Adelaide Hospital and fosters the research program of the GenesisCare Research Network. Professor Worthley graduated from Medicine at the Adelaide University, South Australia. His training included his Cardiology fellowship at the Royal Adelaide Hospital, his PhD at the Mount Sinai Medical Centre in New York, and post-doctoral research and interventional fellowship at Monash Medical Centre, Melbourne. He established the first dedicated Cardiac CT and MR units in the Asia Pacific region, as well as leading the Cardiovascular Research Centre at the University of Adelaide as the Helpman Professor of Cardiovascular Medicine, a position he held between 2004 and 2016.
Job Titles:
- Chief Medical Officer
- Founder
Reynolds M. Delgado III, MD, FACC Founder & Chief Medical Officer Practicing cardiologist and leader in the field of heart failure. Medical Director, Mechanical Support Devices in Heart Failure, Texas Heart Institute; Advisory Board, Boston Scientific (LATITUDE HF monitoring system); Author on two NEJM articles that led to the FDA approval of the Heartmate II™ LVAD. Read full bio
Job Titles:
- Member of the Scientific Advisory Board